Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | PHASE1 | COMPLETED | 6 | — | — | Mar 27, 2020 | Feb 24, 2023 | Mar 16, 2023 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort. |
| Phase 2 | EXPERIMENTAL | The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen. |
| Name | Type | Description |
|---|---|---|
| TC-110 T Cells | DRUG | TC-110 T Cells |
| Fludarabine | DRUG | Flu/Cy Lymphodepletion |
| Cyclophosphamide | DRUG | Flu/Cy Lymphodepletion |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed * Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU * Histologically c...